Top Markets
Coin of the day
Impel Pharmaceuticals Inc. Impel Pharmaceuticals Inc.

Impel Pharmaceuticals Inc.

IMPL
Kedudukan dalam Saham #37159
Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical... Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.
Harga Saham
$0.1011
Disegerakkan terakhir: 2024-01-16
Modal Pasaran
$1.96M
Perubahan (1 hari)
1.10%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Impel Pharmaceuticals Inc. (IMPL)

Kategori

Sejarah pecahan saham untuk Impel Pharmaceuticals Inc. (IMPL)
Saham Impel Pharmaceuticals Inc. (simbol: IMPL) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Aug 15, 2026.
Satu saham IMPL yang dibeli sebelum Aug 15, 2026 kini bersamaan dengan 0 saham IMPL.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
Tidak cukup data untuk tarikh yang disediakan.
Pecahan saham untuk syarikat pesaing atau serupa
Syarikat Bilangan pecahan saham Gandaan Kumulatif Negara
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE